Cardiovascular effects of dose escalating of norepinephrine in healthy dogs anesthetized with isoflurane

Author(s):  
Kazuki Kojima ◽  
Tomohito Isizuka ◽  
Noboru Sasaki ◽  
Kensuke Nakamura ◽  
Mitsuyoshi Takiguchi
2017 ◽  
Vol 44 (4) ◽  
pp. 703-709 ◽  
Author(s):  
Fabiana Micieli ◽  
Bruna Santangelo ◽  
Fabiana Reynaud ◽  
Alessandro Mirra ◽  
Giusy Napoleone ◽  
...  

2000 ◽  
Vol 61 (1) ◽  
pp. 57-60 ◽  
Author(s):  
Suwanakiet Sawangkoon ◽  
Mutsumi Miyamoto ◽  
Tomohiro Nakayama ◽  
Robert L. Hamlin

2014 ◽  
Vol 50 (1) ◽  
pp. 27-35 ◽  
Author(s):  
Janan M. Abed ◽  
Fred S. Pike ◽  
Monica C. Clare ◽  
Benjamin M. Brainard

Sevoflurane and isoflurane are commonly used in veterinary anesthesia. The objective of this prospective, randomized, open-label clinical study was to compare the cardiovascular effects of sevoflurane and isoflurane via direct arterial blood pressure measurements and the lithium dilution cardiac output (LDCO) on premedicated healthy dogs undergoing elective tibial plateau leveling osteotomy (TPLO). Nineteen client-owned dogs were included. All dogs were premedicated with hydromorphone (0.05 mg/kg IV and glycopyrrolate 0.01 mg/kg subcutaneously). Ten dogs were anesthetized with sevoflurane and nine dogs were anesthetized with isoflurane. Eighteen dogs were instrumented with a dorsal pedal arterial catheter, and one dog had a femoral arterial catheter. All dogs had continuous, direct systolic (SAP), diastolic (DAP), and mean arterial (MAP) blood pressure readings as well as heart rate (HR), cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), stroke volume variation (SVV), and pulse pressure variation (PPV) recorded q 5 min during the surgical procedure. There was no significant statistical difference in all parameters between the sevoflurane and isoflurane treatment groups. Both sevoflurane and isoflurane inhalant anesthetics appear to have similar hemodynamic effects when used as part of a multimodal anesthetic protocol in premedicated healthy dogs undergoing an elective surgical procedure.


1998 ◽  
Vol 89 (5) ◽  
pp. 1166-1173 ◽  
Author(s):  
Douglas A. Hettrick ◽  
Paul S. Pagel ◽  
Judy R. Kersten ◽  
John P. Tessmer ◽  
Zeljko J. Bosnjak ◽  
...  

Background Clinical interest in xenon has been rekindled recently by new recycling systems that have decreased its relative cost. The cardiovascular effects of xenon were examined in isoflurane-anesthetized dogs before and after the development of rapid left ventricular (LV) pacing-induced cardiomyopathy. Methods Dogs (n = 10) were chronically instrumented to measure aortic and LV pressure, LV subendocardial segment length, and aortic blood flow. Hemodynamics were recorded, and indices of LV systolic and diastolic function and afterload were determined in the conscious state and during 1.5 minimum alveolar concentration isoflurane anesthesia alone and combined with 0.25, 0.42, and 0.55 minimum alveolar concentration xenon in dogs with and without cardiomyopathy. Results Administration of xenon to healthy dogs anesthetized with isoflurane decreased heart rate and increased the time constant (tau) of isovolumic relaxation but did not alter arterial and LV pressures, preload recruitable stroke work slope, and indices of LV afterload. Chronic rapid LV pacing increased the baseline heart rate and LV end-diastolic pressure, decreased arterial and LV systolic pressures, and produced LV systolic and diastolic dysfunction. Administration of xenon to isoflurane-anesthetized, cardiomyopathic dogs did not alter heart rate, arterial and LV pressures, myocardial contractility, and indices of early LV filling and regional chamber stiffness. More pronounced increases in tau were accompanied by increases in total arterial resistance during administration of xenon to isoflurane-anesthetized cardiomyopathic compared with healthy dogs. Conclusions The results indicate that xenon produces minimal cardiovascular actions in the presence of isoflurane in dogs with and without experimental dilated cardiomyopathy.


2013 ◽  
Vol 95 (2) ◽  
pp. 687-692 ◽  
Author(s):  
V. Saponaro ◽  
A. Crovace ◽  
L. De Marzo ◽  
P. Centonze ◽  
F. Staffieri

Sign in / Sign up

Export Citation Format

Share Document